Pathway To Prevention

Overview

About this study

The overall objective of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for type 1 diabetes (T1D) to:

characterize their risk for developing T1D and identify subjects eligible for prevention trials;
describe the pathogenic evolution of T1D; and
increase the understanding of the pathogenic factors involved in the development of T1D.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Willing and able to provide informed consent.
First degree relatives (age 2.5 – 45 years) of T1D probands.
Second and third degree relatives (age 2.5 – 20 years) of T1D probands: nieces, nephews, aunts, uncles, grandchildren, cousins, half-siblings.
Individuals (age 2.5-45 years) who have diabetes-related autoantibodies potentially eligible for clinical trial.

Exclusion Criteria:

Have diabetes by 2011 ADA criteria.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Ana Creo, M.D.	Open for enrollment	Contact information: Kawser Iguel M.P.H. (507) 422-5291 Iguel.Kawser@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ana Creo, M.D.

Open for enrollment

Contact information:

Kawser Iguel M.P.H.

(507) 422-5291

Iguel.Kawser@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials